Clinical Trial Update: First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM) [Phase 1]

View source ↗

Summary

The first-in-human single ascending dose study of FluoroEthylNorMemantine (FENM) by ReST Therapeutics has been withdrawn; the listed conditions include post-tra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Major Depressive Disorder
• Neurodegenerative Disease
• Post-traumatic Stress Disorder
• Treatment-resistant Depression

Drugs mentioned

• FluoroEthylNorMemantine (FENM) (FluoroEthylNorMemantine)

Snippet

Sponsor: ReST Therapeutics | Conditions: PTSD, Alzheimer Disease | Phase 1 | Status: WITHDRAWN